CNBC, screengrab
Citron Research's Andrew Left went on CNBC's "Halftime Report" to talk about why he's long on Valeant Pharmaceuticals now and his views on another drug maker, Mallinckrodt.
He says that it's worse than Valeant — that Mallinckrodt is the "real offender in the system."
He even showed up with a $1 million check of his own personal cash and said that he would donate it to multiple sclerosis research if MNK would test one of its two flagship drugs. The drug he was referring to is Acthar, and according to Left, it makes up 40% of the company's revenue.
Left famously — or infamously, depending on your point of view — brought Valeant's accounting inconsistencies and shady billing to Wall Street's attention in October. That, combined with government scrutiny over Valeant's drug-pricing practices, combined to bring the company to its knees.
MNK, says Left, is worse than Valeant because its drugs don't really work — thus the $1 million check. He says that its flagship products were approved by the FDA at a time when the agency made sure that drugs weren't harmful, but didn't check that they did what they said they would do.
"If Valeant had done what MNK is doing, I think they [Congress] would've waterboarded [former Valeant CEO Mike] Pearson," he said.
Pearson appeared before Congress to answer for Valeant's price increases at the end of last month.
"There's no reason Valeant should have to reduce prices and MNK not," said Left.
Speaking of Valeant, Left basically said that he's long on the stock simply because he doesn't think it's going to go bankrupt in the next 12 months. Bringing on new CEO Joe Papa makes it look like the company's preparing for a turnaround.
"You still might say the stock is uninvestable," he said. "Would I hold this [VRX] for 18 months? I'd need more information."
This story has been updated.
NOW WATCH: Watch Hillary Clinton threaten to 'go after' one of the most controversial drug companies in America
